Pediatric advanced therapies are an exciting, complex and evolving field. Autologous collections require collaboration between flexible apheresis services and the clinical/research team for success, including quality and reducing error. Mobilization, collection and processing methods impact the final therapeutic product. For haploidentical hematopoietic cell transplantation, Alpha/Beta T-cell Depletion has transformed the approach to donor selection and significantly expanded availability. A modern approach is sophisticated ex vivo processing of the donor graft to remove those cells most responsible for causing GVHD. This session will present examples and discuss the ongoing therapeutic diversification and development in cellular therapy protocols, which will require international collaboration to improve standardization, efficiency, and quality.